• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    AddLife (OM:ALIF B) Following Fresh Results The Valuation Case Is Back In Focus

    Simply Wall St·07/17/2026 02:36:10
    语音播报

    AddLife (OM:ALIF B) released its second quarter and half year 2026 earnings, giving investors fresh numbers on sales, profitability and earnings per share that help frame how the business is currently performing.

    See our latest analysis for AddLife.

    AddLife’s recent earnings release appears to be the key catalyst behind the stock’s 6.29% 7 day share price return and 10.42% year to date share price return, although the 1 year total shareholder return is still down 3.79%.

    If you want to see what else is moving after recent earnings updates, it is a good time to scan for potential opportunities using the 127 healthcare AI stocks

    After this earnings bump and with AddLife trading below both analyst targets and one estimate of intrinsic value, the key issue now is to determine where fair value really sits across that spread.

    Most Popular Narrative: 11.9% Undervalued

    At a last close of SEK167.40 versus a narrative fair value of SEK190, the current pricing for AddLife sits below what the most followed story implies.

    The company plans to leverage its strengthened balance sheet to accelerate acquisition activity, particularly in high-margin and fast-growing segments like orthopedic surgery, which could drive future revenue growth and increase EBITA margins. The successful integration of recent acquisitions, such as BonsaiLab and Edge Medical, with a focus on expanding in high-growth areas and leveraging synergies across its portfolio, is anticipated to contribute positively to revenue and earnings growth.

    Read the complete narrative.

    To understand why this valuation leans on expansion rather than just cost cutting, and how growth, margins and future earnings power tie together in one forecasted arc, the full narrative joins those pieces into a single pricing story.

    Result: Fair Value of SEK190 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, this AddLife narrative could be tested if academic research demand stays weak or if supply chain pressures limit the benefits of higher margin products and acquisitions.

    Find out about the key risks to this AddLife narrative.

    Another View on AddLife Using Market Ratios

    The most followed AddLife narrative leans on future earnings and a fair value of SEK190, yet the current P/E of 35.9x sits slightly above a fair ratio of 35.1x and below the Global Life Sciences average of 39.5x and peer average of 44.4x. This points to a more mixed picture for valuation risk and opportunity. With signals pulling in different directions, which one do you trust first?

    See what the numbers say about this price — find out in our valuation breakdown.

    OM:ALIF B P/E Ratio as at Jul 2026
    OM:ALIF B P/E Ratio as at Jul 2026

    Next Steps

    Given the mix of potential risks and rewards around AddLife, it makes sense to move quickly, review the numbers yourself, and see how your view compares to the 3 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond AddLife?

    If AddLife has sharpened your focus, now is the moment to broaden your watchlist with other targeted ideas before the best opportunities move on.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.